+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders



Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders



Rhode Island Medical Journal 97(10): 20-24



Substance use disorders are a leading cause of morbidity and mortality in the United States. Medications for the treatment of substance use disorders are effective yet underutilized. This article reviews recent literature examining medications used for the treatment of alcohol and opioid use disorders. The neurobehavioral rationale for medication treatment and the most common ways medications work in the treatment of substance use disorders are discussed. Finally, the medications and the evidence behind their effectiveness are briefly reviewed. Physicians and other prescribing clinicians should take an active role in facilitating remission and recovery from substance use disorders by prescribing these effective medications with brief medical management counseling.

(PDF emailed within 1 workday: $29.90)

Accession: 054314742

Download citation: RISBibTeXText

PMID: 25271655


Related references

The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders. American Journal on Addictions 24(8): 722-731, 2016

Opioid drugs in maintenance and detoxification treatment of opiate addiction; addition of buprenorphine and buprenorphine combination to list of approved opioid treatment medications. Interim final rule. Federal Register 68(99): 27937-9, 2003

Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule. Federal Register 77(235): 72752-72761, 2012

Prescribing for buprenorphine in the treatment of opioid addiction. Psychiatry: 16, 2007

Clinical Update of Opioid Agonist and Partial Agonist Medications for the Maintenance Treatment of Opioid Addiction. Seminars in Neuroscience 9(3-4): 140-157, 1997

Emergency Department Treatment of Opioid Addiction: An Opportunity to Lead. Academic Emergency Medicine 25(5): 601-604, 2017

Relapse prevention medications in community treatment for young adults with opioid addiction. Substance Abuse 37(3): 392-397, 2016

A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction. Journal of Addiction Medicine 10(2): 93-103, 2016

Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder. Addiction 2018, 2018

Provider perceptions of system-level opioid prescribing and addiction treatment policies. Current Opinion in Psychology 30: 65-73, 2019

Medications for Alcohol and Opioid Use Disorders and Risk of Suicidal Behavior, Accidental Overdoses, and Crime. American Journal of Psychiatry 175(10): 970-978, 2018

Functional relevance of μ-δ opioid receptor heteromerization: a role in novel signaling and implications for the treatment of addiction disorders: from a symposium on new concepts in mu-opioid pharmacology. Drug and Alcohol Dependence 121(3): 167-172, 2012

Perioperative Management of Patients with Addiction to Opioid and Non-opioid Medications. Current Pain and Headache Reports 22(7): 52, 2018

Factors affecting clinicians' decision as to whether to prescribe psychotropic medications or not in treatment of tic disorders. Brain and Development 34(1): 39-44, 2012

Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. Progress in Brain Research 223: 253-267, 2017